# SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

> **NCT05582122** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 420 (estimated)

## Conditions studied

- Oropharynx Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** HPV16 Ct-DNA dosing

## Key facts

- **NCT ID:** NCT05582122
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2028-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582122, "SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05582122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*